IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Earnings per Share
Based on net in come from con tin u ing op er a tions di luted earn ings per share (EPS) in 2008 was $3.59, up
28% from $2.81 in 2007. A di rect com par i son in clud ing dis con tin ued op er a tions re sults in a re duc tion in
EPS of 30% from 2007 to 2008.
$
6.0
5.0
4.0
3.0
2.0
1.0
0.0
R&D Costs
Earnings Per Share
2004 2005 2006 2007 2008
Source: Novartis January 2009/Novartis Annual Reports
In 2008, Novartis in creased R&D spend ing by 12.2% to $7,217 mil lion, rep re sent ing 17.4% of sales, up
from 16% in 2007.
$ millions
8,000
7,000
6,000
5,000
4,000
3,000
2,000
1,000
0
Sales by Business Sector
R&D Costs
2004 2005 2006 2007 2008
Source: Novartis January 2009/Novartis Annual Reports
Pharmaceuticals ac counted for 63.5% of Novartis net sales from con tin u ing op er a tions in 2008, Sandoz
for 18.2%, Con sumer Health for 14% and Vac cines and Di ag nos tics for 4.2%. Pharmaceuticals net sales
were up 9.6% (5% in lo cal cur rency terms) to $26.3 bil lion. The On col ogy and Car dio vas cu lar fran chises
pro vided dy namic per for mances, in clud ing Diovan with sales of $5.7 bil lion and Glivec with $3.7 bil lion.
Sales of $2.9 bil lion came from re cently launched prod ucts in clud ing Aclasta/Reclast, Tekturna, Exforge,
Lucentis, Exelon Patch, Tasigna and Xolair.
© 2009 IMS Health In cor po rated or its af fil i ates Page 17